12:00 AM
 | 
May 10, 2004
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Genta Inc.

(GNTA), Berkeley Heights, N.J.

Business: Cancer

Rodman & Renshaw analyst Ren Benjamin lowered his rating to "market perform/speculative risk" from "market outperform/speculative risk." Last week, FDA's Oncologic Drugs Advisory Committee voted 13-3 that the...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >